Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
panobinostat/LBH589B · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Panobinostat | EXPERIMENTAL | - |
| LBH589 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Panobinostat | DRUG | Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8 Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5 Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8 |
| Cytarabine | DRUG | Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9. Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7. Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9. |
| Daunorubicin | DRUG | Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5. Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4. Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5. |
| panobinostat/LBH589B | DRUG | - |
Inclusion Criteria: * Untreated histologically confirmed acute myeloid leukemia OR advanced myelodysplastic syndrome (INT-2 or High risk) not previously treated with anthracycline-based chemotherapy OR a therapy-related myeloid neoplasm * Male or female aged ≥ 60 years * ECOG performance status 0-2...
Panobinostat is an investigational small molecule being studied for multiple oncology indications, including multiple myeloma in relapse, myelodysplastic syndromes (MDS), refractory leukemia, mantle cell lymphoma, prostate cancer, and Hodgkin's lymphoma. It is currently in Phase 1 clinical development and is not approved by the FDA.
Panobinostat is being developed by Novartis AG, which trades under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various cancer types, including Hodgkin's lymphoma and multiple myeloma.
Panobinostat is currently in Phase 1 clinical development. While some completed trials have explored Phase 2 and Phase 3 settings, the drug's overall development stage is Phase 1, and it remains investigational, not approved for any indication.
Panobinostat has been studied in several completed trials, including NCT00742027 for relapsed/refractory classical Hodgkin's lymphoma, NCT01034163 for maintenance in Hodgkin's lymphoma, NCT01083602 for relapsed and bortezomib-refractory multiple myeloma, and NCT01504776 for mantle cell lymphoma. All trials are completed.
Panobinostat is also known by the alternative name LBH589. This alternative name may appear in clinical trial registries and scientific literature, referring to the same investigational drug being developed by Novartis for oncology indications.
Panobinostat is a small molecule that targets histone deacetylases (HDACs), enzymes involved in gene expression regulation. By inhibiting HDAC activity, it may alter cancer cell growth and survival pathways. However, specific molecular targets have not been detailed in the available information.